Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet
Open Access
- 16 March 2012
- journal article
- Published by Wiley in The FEBS Journal
- Vol. 279 (10), 1883-1893
- https://doi.org/10.1111/j.1742-4658.2012.08569.x
Abstract
Although improving glucose metabolism by inhibition of pyruvate dehydrogenase kinase 4 (PDK4) may prove beneficial in the treatment of type 2 diabetes or diet‐induced obesity, it may have detrimental effects by inhibiting fatty acid oxidation. Peroxisome proliferator‐activated receptor α (PPARα) agonists are often used to treat dyslipidemia in patients, especially in type 2 diabetes. Combinational treatment using a PDK4 inhibitor and PPARα agonists may prove beneficial. However, PPARα agonists may be less effective in the presence of a PDK4 inhibitor because PPARα agonists induce PDK4 expression. In the present study, the effects of clofibric acid, a PPARα agonist, on blood and liver lipids were determined in wild‐type and PDK4 knockout mice fed a high‐fat diet. As expected, treatment of wild‐type mice with clofibric acid resulted in less body weight gain, smaller epididymal fat pads, greater insulin sensitivity, and lower levels of serum and liver triacylglycerol. Surprisingly, rather than decreasing the effectiveness of clofibric acid, PDK4 deficiency enhanced the beneficial effects of clofibric acid on hepatic steatosis, reduced blood glucose levels, and did not prevent the positive effects of clofibric acid on serum triacylglycerols and free fatty acids. The metabolic effects of clofibric acid are therefore independent of the induction of PDK4 expression. The additive beneficial effects on hepatic steatosis may be due to induction of increased capacity for fatty acid oxidation and partial uncoupling of oxidative phosphorylation by clofibric acid, and a reduction in the capacity for fatty acid synthesis as a result of PDK4 deficiency.Keywords
This publication has 36 references indexed in Scilit:
- Pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) deficiency attenuates the long-term negative effects of a high-saturated fat dietBiochemical Journal, 2009
- Treatment of hyperlipidaemia with fenofibrate and related fibratesExpert Opinion on Investigational Drugs, 2008
- Pyruvate dehydrogenase kinase-4 deficiency lowers blood glucose and improves glucose tolerance in diet-induced obese miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Estrogen-related Receptors Stimulate Pyruvate Dehydrogenase Kinase Isoform 4 Gene ExpressionOnline Journal of Public Health Informatics, 2006
- Role of pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) in glucose homoeostasis during starvationBiochemical Journal, 2006
- Fenofibrate, a peroxisome proliferator‐activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liverLiver International, 2006
- Adaptive Increase in Pyruvate Dehydrogenase Kinase 4 during Starvation Is Mediated by Peroxisome Proliferator-Activated Receptor αBiochemical and Biophysical Research Communications, 2001
- A Role for Estrogen-related Receptor α in the Control of Mitochondrial Fatty Acid β-Oxidation during Brown Adipocyte DifferentiationOnline Journal of Public Health Informatics, 1997
- Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.JCI Insight, 1995
- Die enzymatische analyse von coenzym ABiochimica et Biophysica Acta (BBA) - Specialized Section on Enzymological Subjects, 1963